Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Abbott Laboratories (ABT)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
111.48+0.99 (+0.90%)
At close: 04:04PM EDT
110.99 -0.49 (-0.44%)
After hours: 07:59PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close110.49
Open110.86
Bid111.28 x 900
Ask111.32 x 800
Day's Range110.43 - 111.53
52 Week Range101.24 - 142.60
Volume2,813,381
Avg. Volume4,969,816
Market Cap195.226B
Beta (5Y Monthly)0.70
PE Ratio (TTM)23.27
EPS (TTM)4.79
Earnings DateOct 18, 2022 - Oct 24, 2022
Forward Dividend & Yield1.88 (1.70%)
Ex-Dividend DateJul 14, 2022
1y Target Est127.91
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-22% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for ABT

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Abbott Laboratories
    Weekly Stock ListLast week was the busiest of the quarter for earnings, with many sharp stock-price moves following above- or below-consensus results or changes in guidance. Through July 26, Refinitiv noted that 133 S&P 500 companies had reported earnings, with 76% beating expectations, above the long-term average of 66%. The blended (actual for those reporting and consensus for those still to report) growth rate is 6.2%, near the 5.6% expectation and indicating the "beats" have not been robust. But the sour mood coming into the quarter is being greeted with relief that profit shortfalls and lowered guidance are not rampant. Our analysts always look for companies that boost outlooks during earnings season. Raising guidance can be a catalyst for strong returns in the quarters ahead. Here is an initial list of BUY-rated companies in Argus coverage with raised guidance or increased outlooks during the 2Q22 EPS reporting season.
    Rating
    Fair Value
    Economic Moat
    12 days agoArgus Research
View more
  • Benzinga

    MedTech Giant Abbott To Inject Over €400M In Ireland To Expand Production Of Glucose Monitoring Tech

    Abbott Laboratories (NYSE: ABT) is investing €440 million in Ireland with plans for a major new manufacturing plant in Kilkenny and additional jobs in Donegal, state investment agency IDA Ireland said. The company plans to hire 1,000 people in Ireland, which has 5,000 staff in the country. Abbott will expand its manufacturing facilities in the northwest county of Donegal and build a new plant at the other end of the country in Kilkenny. Subject to planning permission, the new 250,000 sq. ft. man

  • News Direct

    Bridging the Access Gap for Health Tech

    Abbott, leading experts discuss how technology can transform the future of healthcare at Aspen Ideas: Health event.

  • Insider Monkey

    11 Best Falling Stocks To Buy Now

    In this article, we talk about 11 best falling stocks to buy now. If you wish to skip our detailed analysis of the latest market situation, go directly to 5 Best Falling Stocks To Buy Now. After a brutal 2022 which saw the S&P500 shed more than 21% in the first half of the year, Q2 […]

Advertisement
Advertisement